Identifying new treatments for cancers with BRCA1/2 mutations by targeting a specific protein.
Official title: Chemoproteomic discovery and characterization of covalent ligands for the oncoprotein CIP2A, a unique vulnerability in BRCA1/2-deficient cancers
Funded at Rockefeller University · NIH-11063123 · Data updated 2026-11-12
This study is looking at a specific type of cancer that has changes in the BRCA1/2 genes and is testing a new way to target a protein called CIP2A that helps these cancer cells survive, with the hope of creating treatments that are more effective and kinder to healthy cells.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $78,040 |
| NIH project number | 5F32CA284727-02 |
| Project ID | NIH-11063123 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with BRCA1 or BRCA2 mutations who are suffering from related cancers.
✕Less likely to help
Patients without BRCA1/2 mutations or those with cancers that do not rely on CIP2A for survival may not benefit from this research.
What this research studies
This research focuses on cancers that have mutations in the BRCA1/2 genes, which are crucial for DNA repair. It investigates a protein called CIP2A, which is essential for the survival of these cancer cells. By using innovative techniques to identify and develop covalent ligands that can inhibit CIP2A, the research aims to create targeted therapies that specifically affect BRCA1/2-deficient cancers while sparing healthy cells. This approach could lead to more effective and less harmful cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and reduce side effects for patients with BRCA1/2-deficient cancers.
How similar studies have gone: While targeting CIP2A is a novel approach, previous research has shown success in developing therapies for other cancer vulnerabilities, indicating potential for this strategy.
Where this research is happening
-
Rockefeller University
New York, United States Active
Researchers
- Principal investigator: Heiss, Tyler — Rockefeller University
- Study coordinator: Heiss, Tyler
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.